The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.
X. G. Thomas
No relevant relationships to disclose
A. Dmoszynska
Research Funding - MGI Pharma
Other Remuneration - Celgene
A. Wierzbowska
No relevant relationships to disclose
K. Kuliczkowski
No relevant relationships to disclose
J. Mayer
No relevant relationships to disclose
T. Shelekhova
No relevant relationships to disclose
J. Gau
No relevant relationships to disclose
W. Chou
No relevant relationships to disclose
R. Buckstein
No relevant relationships to disclose
J. Cermak
No relevant relationships to disclose
C. Kuo
No relevant relationships to disclose
A. O. Rocafiguera
No relevant relationships to disclose
V. Koza
No relevant relationships to disclose
F. Ravandi
Honoraria - Eisai; Johnson & Johnson
Research Funding - Eisai
H. Kantarjian
Research Funding - Eisai